Tlr7 links for the treatment of hepatitis c.

The use of a TLR7 ligand for the manufacture of a medicament for the treatment of a hepatitis C virus infection in a patient, in which the TLR7 ligand is selected from ** (See formula) ** in which: each R1 is H or a substituted or unsubstituted alkyl, alkenyl or alkynyl, which may be interrupted with one or more heteroatoms O, S or N, or a substituted or unsubstituted aryl or heteroaryl; R2 is H, OH, SH, halo or a substituted or unsubstituted alkyl, alkenyl or alkynyl, which may be interrupted with one or more heteroatoms O, S or N, or an -O- (alkyl), -O- (aryl), -O- (heteroaryl), -S- (alkyl), -S- (aryl), -S- (heteroaryl), aryl or heteroaryl substituted or unsubstituted; R3 is H, OH or SH, or an alkyl, alkenyl, alkynyl, aryl, heteroaryl, -O- (alkyl), -O- (aryl), -O- (heteroaryl), -S- (alkyl), -S- (aryl), -S- (heteroaryl), -NH (alkyl), -NH (aryl), -NH (heteroaryl), -NH (R4) (alkyl ), -NH (R4) (aryl) or -NH (R4) (substituted or unsubstituted heteroaryl), in which R4 is a substituted or unsubstituted alkyl; X is O or S; Y is H, halo, OH, OR4, SH, SR4 or a substituted or unsubstituted alkyl or aryl; Z is H, halo, OH, OR4, SH or SR4; or a pharmaceutically acceptable salt, hydrate or stereoisomer thereof or a pharmaceutically acceptable salt or hydrate of said stereoisomer.